Human cluster of differentiation 30(CD30) ELISA Kit

Instructions
Code CSB-E17502h
Size 96T,5×96T,10×96T
See More Details 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name tumor necrosis factor receptor superfamily, member 8
Alternative Names CD 30 ELISA Kit; CD30 ELISA Kit; CD30 antigen ELISA Kit; CD30L receptor ELISA Kit; Cytokine receptor CD30 ELISA Kit; D1S166E ELISA Kit; KI 1 ELISA Kit; KI 1 antigen ELISA Kit; Ki-1 antigen ELISA Kit; KI1 ELISA Kit; Lymphocyte activation antigen CD30 ELISA Kit; TNFRSF 8 ELISA Kit; Tnfrsf8 ELISA Kit; TNR8_HUMAN ELISA Kit; Tumor necrosis factor receptor superfamily member 8 ELISA Kit
Abbreviation TNFRSF8
Uniprot No. P28908
Species Homo sapiens (Human)
Sample Types serum, plasma, cell culture supernates
Detection Range 15.6 pg/mL-1000 pg/mL
Sensitivity 3.9 pg/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Others
Assay Principle quantitative
Measurement Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human CD30 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
SampleSerum(n=4)
1:100Average %90
Range %84-96
1:200Average %97
Range %91-105
1:400Average %103
Range %97-107
1:800Average %89
Range %83-94
Recovery
The recovery of human CD30 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 10094-105
EDTA plasma (n=4)106101-110
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/mlOD1OD2AverageCorrected
10002.811 2.762 2.787 2.661
5002.578 2.402 2.490 2.364
2502.166 1.997 2.082 1.956
1251.312 1.355 1.334 1.208
62.50.645 0.652 0.649 0.523
31.20.398 0.395 0.397 0.271
15.60.223 0.236 0.230 0.104
00.127 0.125 0.126
Troubleshooting
and FAQs
ELISA kit FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Target Data

Function Receptor for TNFSF8/CD30L. May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa-B.
Gene References into Functions
  1. Data suggest that CD4+ T cell-associated HIV-1 RNA is often highly enriched in cells expressing CD30; cells expressing this marker considerably contribute to total pool of transcriptionally active CD4+ lymphocytes in individuals on suppressive anti-retroviral drug therapy; CD30 may be a marker of residual, transcriptionally active HIV-1 infected cells in blood and in gut-associated lymphoid tissue. PMID: 29470552
  2. The stable elevation in classical Hodgkin lymphoma risk with elevated levels of sCD30 and IL6 across 4 or more years prior to diagnosis may also reflect a B-cell-stimulatory environment that promotes the genesis of these cancers. PMID: 28341757
  3. extranodal NK/T-cell lymphoma, nasal type(ENKTL) is the most common type of mature T-cell and NK-cell lymphoma diagnosed at our institution. CD30 is frequently expressed in ENKTL and represents a therapeutic target; however, it may not be a prognostic marker. PMID: 28486951
  4. This study suggests that in patients with CD30+ lymphoproliferative disorders, an aggressive clinical course cannot be defined by the presence of TP63 rearrangements, as was recently shown in systemic ALK negative anaplastic large cell lymphoma. PMID: 27146432
  5. Data suggest that Brentuximab Vedotin (SGN-35) damaged CD30 ligand (CD30L)-immune cells through CD30 extracellular vesicles (EVs). PMID: 27105521
  6. median FoxP3+ Treg count was higher in CD30+ than in CD30- posttransplant lymphoproliferative disorders, 3.0 vs 0 PMID: 29126177
  7. Variant histology is common in pediatric NLPHL, especially types C and E, which are associated with IgD expression. Type C variant histology and possibly type D are associated with decreased EFS, but neither IgD nor CD30 are adverse features. Variant histology may warrant increased surveillance, but did not affect overall survival. PMID: 28802087
  8. Expression of CD30 in patients with both DLBCL and other aggressive B-cell lymphomas and the absence of MYC oncogene-driven proliferation in the majority of these tumors suggests that brentuximab may be a particularly effective form of targeted therapy in the subset of patients with high CD30 expression. PMID: 27521276
  9. Prevalence of the CD30 (Ki-1) antigen in human solid tumors was summarized. PMID: 28427526
  10. Higher serum sCD30 levels were associated with an increased risk of bacterial infection after kidney transplantation. PMID: 28122147
  11. CD30 expression was detected in up to 25% of cases of diffuse large B-cell lymphoma and was more frequent in tumors without MYC rearrangement. CD30 expression was not associated with overall survival in R-EPOCH-treated de novo DLBCL patients. PMID: 27816715
  12. CD30 facilitates phosphorylation of heat shock factor 1, activates heat shock promoter element, and induces heat shock protein (HSP) 90. PMID: 27870927
  13. this study shows that polyclonal and allogeneic stimulation induced higher levels of CD30 transcripts in end-stage renal disease patients compared to control patients PMID: 26970513
  14. CD30 expression was not associated with prognosis in our cohort of de novoDLBCL, including in patients who received aggressive chemotherapy. CD30 expression and MYC rearrangement were mutually exclusive in de novoDLBCL. PMID: 26340843
  15. Case Report: CD30 positive lymphomatoid papulosis arising in association with cutaneous amyloidosis in a patient with multiple myeloma. PMID: 26981738
  16. The heterogeneity of CD30 expression in refractory or relapsed peripheral T-cell lymphoma patients indicates the likelihood for better response for patients with strong CD30 expression by tumor cells. PMID: 26703966
  17. CD30 may be useful as a prognostic marker in rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treated DLBCLs, indicating favorable outcomes in a Chinese population. PMID: 26884853
  18. this review is focused on the role of CD30 receptor and p53 as novel targets for therapy in ALK+ ALCL, and also provides an update on their potential involvement in ALK+ ALCL pathogenesis PMID: 26709646
  19. Most angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma-not otherwise specified express variable levels of CD30. PMID: 26574847
  20. Upregulated expression of CD30 is commonly found in sclerosing angiomatoid nodular transformation of the spleen. PMID: 26261484
  21. Our results demonstrated significantly elevated sCD30 levels in AS patients compared to healthy controls (HCs) with mean values of 32.0 +/- 12.2 and 24.9 +/- 8.0 ng/mL, (P(**) = 0.007), suggesting a p role of sCD30 in the pathogenesis of AS. PMID: 26273636
  22. With the introduction of the immunoconjugate brentuximab vedotin, the CD30 antigen has become an effectively targetable molecule. Therefore, we investigated the frequency and level of CD30 expression in post-transplant lymphoproliferative disorders. PMID: 25248878
  23. Data susggest that CD30 antigen may be useful as a prognostic factor and therapeutic target in extranodal natural killer/T-cell lymphoma (NKTCL). PMID: 25288491
  24. Data indicate that CD30 antigen downregulation and P-Glycoprotein (MDR1) upregulation are associated with drug resistance to brentuximab vedotin. PMID: 25840583
  25. Intralymphatic variant of ALCL and LyP may be explained, at least in part, by a particular lymphotropism of the neoplastic cells of cutaneous CD30 lymphoproliferative disorders. PMID: 26371781
  26. BAG-3 expression correlated with increased HSP70 expression in a subset of systemic T cell lymphoma cases co-expressing the CD30 antigen. PMID: 24492285
  27. These results show that high sCD30 levels are independent predictors of graft dysfunction PMID: 25698648
  28. Single threonine residue at position 61 in CD30v that is critical for TRAF2 interaction, NFkappaB activation, and downstream CD30-NFkappaB-dependent phenotypes in hESCs was identified. PMID: 25568342
  29. Case Report: describe a CD30+ lymphoproliferative rash exhibiting a predilection for recurrence on the same skin sites. PMID: 24733405
  30. case Report: primary cutaneous CD30+ anaplastic large cell lymphoma treated successfully with brentuximab vedotin. PMID: 24733422
  31. Elevated serum sCD30 is associated with increased risk of non-Hodgkin lymphoma. PMID: 25567136
  32. Case Report: suggest Sezary syndrome, CD30 anaplastic large-cell lymphoma, and mycosis fungioides are interrelated. PMID: 25548993
  33. levels of serum sCD30 tend to be higher in individuals with atopy. Improvement in lung function seems to be associated with a decrease in sCD30 in children with atopy and troublesome lung symptoms. PMID: 25492095
  34. occurs in a significant subset of angiosarcomas and epithelioid hemangioendotheliomas PMID: 24805132
  35. findings uncover the oncogenic role of the JUNB/CD30 axis and its potential as therapeutic target in ALK+ ALCL. PMID: 25145835
  36. Data indicate a chimeric fusion involving nucleophosmin NPM1 (5q35) and TYK2 kinase (19p13) that encodes an NPM1-TYK2 protein in cutaneous CD30 antigen-positve lymphoproliferative disorders. PMID: 25349176
  37. is expressed in a substantial proportion of DLBCL and CD30 immunohistochemistry may be a useful prognostic marker in R-CHOP treated GCB-DLBCL. PMID: 25135752
  38. The expression of CD30 by mastocytosis mast cells may influence the clinical phenotype and management of mastocytosis. (Review) PMID: 24745678
  39. a substantial subset of patients with T-ALL have lymphoblasts that express surface CD30. CD30 expression by T-lymphoblasts also appears to be up-regulated in patients who are treated with high-dose chemotherapy. PMID: 23937105
  40. Suggest intralymphatic cutaneous anaplastic large cell lymphoma/lymphomatoid papulosis are part of an expanding spectrum of CD30-positive lymphoproliferative disorders. PMID: 24805854
  41. higher serum levels in Ewing sarcoma patients with primary bone tumors PMID: 24375064
  42. diagnostic and prognostic value of CD30 expression in systemic mastocytosis as assessed by multiparameter flow cytometry PMID: 24111625
  43. this study highlights a novel SATB1-p21 axis that plays an important role in the disease progression of cutaneous CD30+LPDs, which provides novel molecular insights into this disease and possibly leads to new therapies in the future. PMID: 24747435
  44. serum concentration during pregnancy is not associated with pre-eclampsia and recurrent pregnancy loss PMID: 23268289
  45. CD30 expression on lymphomatous cells makes an attractive target for drug-conjugated antibody-directed therapies. PMID: 23716537
  46. CD30(+) peripheral T-cell lmyphomas differed significantly from CD30(-) samples. PMID: 23716562
  47. Post-transplant sCD30 serum levels, especially in conjunction with information regarding HLA class II antibodies and serum creatinine levels, provide valuable information regarding graft outcome PMID: 23928467
  48. Malignant Hodgkin and Reed-Sternberg cells release CD30 on the surface of extracellular vesicles facilitating CD30-CD30L interaction between cell types. PMID: 24659185
  49. High pretransplant levels of serum soluble CD30 can be a risk factor for kidney transplant rejection, and its high negative predictive value at various cutoffs make it useful to find candidates with a low risk of acute rejection after transplant. PMID: 23477385
  50. Soluble CD30 levels are significantly reduced in combination immunosuppression but are differentially affected by different immunosuppressant agents. PMID: 23503451
  51. Routine testing of CD30 may identify candidates for anti-CD30 targeted therapy. PMID: 23797717
  52. These results suggest that CD30 could play a role in the pathogenesis of systemic lupus erythematosus and its expression on CD3 T lymphocytes is not restricted only to Th2-type response PMID: 23790231
  53. Allostimulation results in the up-regulation of the T-cell activation marker CD30 on CD4 as well as CD8 memory T cells and increased release of sCD30 from these cells in an IFN-gamma- and IL-2-dependent manner. PMID: 23857000
  54. The data suggest that patients with acute myeloid leukemia displaying the high-risk FLT3-ITD mutation, have a high likelihood of having CD30 expression on myeloblasts. PMID: 22966913
  55. RIP1 is a crucial mediator of CD30-induced cell death in anaplastic large-cell lymphoma cells. PMID: 23545938
  56. There is the association between high levels of soluble serum CD26 and CD30 and disease severity. PMID: 23654079
  57. High CD30 expressison is associated with primary effusion lymphoma. PMID: 23244086
  58. It seems appropriate to consider CD30(+) diffuse large B-cell lymphoma as a distinct subgroup. PMID: 23343832
  59. Data indicate that the relative numbers of TNFAIP3/CD30 cells were distributed among three groups, corresponding to those having homozygous (11%), heterozygous (32%), and no (57%) deletions in TNFAIP3. PMID: 23039325
  60. serum sCD30 levels increased and correlated significantly with disease activity in rheumatoid arthritis patients. PMID: 22193227
  61. end-stage renal failure (ESRF) patients showed increased serum sCD30 levels and lower percentages of circulating Tregs as compared to healthy controls PMID: 22940451
  62. Analysis was performed on correlation between soluble CD30 level and acute rejection, lung infection, or renal graft loss respectively. PMID: 23079227
  63. Tumor cell nuclear diameter and CD30 expression were related to survival in extranodal NK/T-cell lymphoma, nasal type. PMID: 23119111
  64. Distinct motifs in the intracellular domain of human CD30 differentially activate canonical and alternative transcription factor NF-kappaappaB signaling. PMID: 23028875
  65. a novel and unexpected role for CD30/CD30L that contributes to proinflammatory immune responses PMID: 22628304
  66. Data show that upregulation of sCD30, iATP, granzyme B, perforin, and downregulation of HLA-G5 could provide valuable diagnostic standards to identify those recipients in the risk of acute rejection (AR). PMID: 22759804
  67. increased in serum of ulcerative colitis and Crohn's disease patients PMID: 22451116
  68. higher levels of soluble protein in kidney transplant recipients suffering graft loss PMID: 22446727
  69. Describe pityriasis lichenoides et varioliformis acuta with numerous CD30(+) cells sharing features of lymphomatoid papulosis and other cutaneous lymphomas. PMID: 22472952
  70. indicate that CD30 is involved in the tumorigenic process of Hodgkin lymphoma (HL), and that it may be useful as a therapeutic target for the treatment of HL PMID: 22715589
  71. Scattered or diffuse CD30 expression in T-MF was not associated with an absence of CXCR3 expression. PMID: 22369302
  72. monitoring of HLA and MICA antibodies as well as sCD30 levels early after transplant has predictive value for early and late allograft dysfunctions and the presence of these factors are detrimental to graft function and survival. PMID: 22182633
  73. CD30-targeted therapy in combination with galectin-1 treatment may induce effective killing of ALCL cells but not of HL cells PMID: 21986812
  74. [REVIEW] observations suggest that advanced systemic mastocytosis has to be considered as a differential diagnosis of CD30-positive lymphoid neoplasms PMID: 21261503
  75. Soluble CD30 and Hepatocyte growth factor as predictive markers of antibody-mediated rejection of the kidney allograft. PMID: 21376809
  76. The association of CD23 and CD30 antigen blood levels with the development of non-Hodgkin lymphoma in HIV patients is reported. PMID: 21860351
  77. posttransplant measurement of sCD30 on day 30 may have a role in subsequent graft loss in kidney transplant recipients PMID: 21505378
  78. CD30 is preferentially expressed in neoplastic mast cells in advanced mast cell neoplasms. PMID: 21186345
  79. The data provide evidence that sCD30 can be used as a marker for diagnosing Epstein-Barr virus-associated lymphoproliferative diseases. PMID: 21181928
  80. reduction in serum post-transplant levels correlates with full graft function PMID: 20600901
  81. High serum levels post-transplantation is associated with poorer graft function at one year PMID: 20600903
  82. increase in serum levels predicts graft-versus-host-disease following allogeneic hematopoietic stem cell transplantation PMID: 20620210
  83. The concentration of sCD30 in maternal serum from preeclamptic women did not differ in comparison with values from healthy controls or pregnancies complicated by isolated fetal intrauterine growth restriction. PMID: 20591497
  84. Case Report: Maculopapular drug eruption to valsartan, an angiotensin II receptor 1 antagonist, which was followed by the development of CD30+ pseudolymphomatous lesions. PMID: 20814632
  85. These data suggested the potential role of aberrant lipid raft/GM1 on CD4+ T cells and soluble CD30 in the pathogenesis of systemic Lupus erythematosus. PMID: 20625494
  86. Data show that the activation induced suppressive FOXP3(+) Tregs can be distinguished by surface expression of CD30 from nonsuppressive FOXP3(+) effector cells. PMID: 20631311
  87. Altered expression of CD30 and the Il-15 regulation of CD30 highlight the occurrence of peripheral manifestations of celiac disease. PMID: 20166880
  88. A significant drop of soluble CD30 kidney transplantation was recorded, but serial measurements did not show a difference among subjects who displayed acute rejection episodes. PMID: 20430176
  89. Measurement of the soluble CD30 level on day 14 after transplant might offer a noninvasive means for recognizing patients at risk of acute graft rejection during the early posttransplant period. PMID: 20353374
  90. Pre-transplant soluble CD30 levels is a predictor of acute rejection, graft loss and pneumonia in renal transplant recipients PMID: 20036333
  91. CD30 antigen is of importance in cell development, and proliferation and is also pathway-related to terminal differentiation in many fetal tissues and organs. PMID: 16244703
  92. CD30/CD95 crosstalk experiments showed that CD30 ligation leads to NF-kappaB-mediated c-FLIP upregulation in cutaneous lymphoma cells, which in turn conferred enhanced resistance to CD95-mediated apoptosis PMID: 19890350
  93. Younger kidney transplant patients had higher sCD30 concentrations however no correlation existed between the serum concentrations and occurrence of rejection episodes or graft survival. PMID: 20061689
  94. Higher levels of soluble CD30, IFN-gamma, and IL-10 posttransplantation in rejecting patients provided evidence for coexistence of cellular and humoral responses in acute kidney graft rejection. PMID: 19765439
  95. expression in T cells up-regulated by CD30L PMID: 11728464
  96. Differential expression of CD30 and p80 between peripheral blood and bone marrow lymphoma cells is a property of the small cell variant of anaplastic large cell lymphoma. PMID: 11891807
  97. constitutive signaling by CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells PMID: 11971184
  98. Single-cell analysis of CD30+ cells in lymphomatoid papulosis demonstrates a common clonal T-cell origin. PMID: 12091351
  99. CD30, but not 4-1BB or OX-40, is preferentially induced by alloantigen, suggesting that CD30 may be important in human alloimmune responses PMID: 12165500
  100. REVIEW: CD30-mediated signal transduction pathways and possible roles in Hodgkins disease and anaplastic large cell lymphoma PMID: 12389614

Show More

Hide All

Subcellular Location Isoform 1: Cell membrane, Single-pass type I membrane protein, SUBCELLULAR LOCATION: Isoform 2: Cytoplasm
Database Links

HGNC: 11923

OMIM: 153243

KEGG: hsa:943

STRING: 9606.ENSP00000263932

UniGene: Hs.1314

Most popular with customers

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

Copyright © 2007-2018 www.cusabio.com CUSABIO TECHNOLOGY LLC All Rights Reserved. 鄂ICP备15011166号-1